Dr. Daver Discusses Single-Agent Immunotherapy in AML

Video

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia.

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia (AML).

Although single agent PD-1 inhibition has not shown activity in AML, single agent CTLA-4 inhibition may have a role, says Daver. For example, promising data has been shown with ipilimumab (Yervoy) as a single agent in patients with AML.

Not all checkpoint inhibitors are equal, says Daver, and combinations will likely be the future of immunotherapy in AML.

Related Videos
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD